首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1684413

重組蛋白治療 CDMO 市場，按類型、按適應症、按來源、按國家和地區 - 2025 年至 2032 年的行業分析、市場規模、市場佔有率和預測

Recombinant Protein Therapeutics CDMO Market, By Type, By Indication, By Source, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2025年03月04日 | 出版商:

AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

報告重點

2024 年重組蛋白治療 CDMO 市場規模價值為 209.2032 億美元，2025 年至 2032 年的複合年成長率為 13.98%。

重組蛋白治療 CDMO 市場 - 市場動態

生物製劑需求的不斷成長和生物加工技術的發展預計將推動市場需求

重組蛋白治療 CDMO 市場的成長受到生物製劑需求不斷成長的推動，再加上生物製劑生產的複雜性，促使製藥和生物技術公司依賴專門的 CDMO。生物相似藥是原始生物製劑的經濟高效版本，正在獲得市場認可，進一步推動重組蛋白生產對 CDMO 服務的需求，促進市場成長。一次性生物反應器、連續製造和高產量表達系統（如CHO和HEK293細胞）提高了蛋白質生產的效率。上游和下游加工的創新提高了蛋白質的產量，降低了整體生產成本和時間。

個人化醫療和精準治療的興起增加了對客製化重組蛋白的需求。基於重組蛋白的細胞和基因療法正在擴大 CDMO 在先進生物製劑中的作用。此外，腫瘤學、罕見疾病和再生醫學領域的新興應用正在推動市場成長。亞太地區，特別是中國、印度和韓國，由於成本較低和政府支持政策，正在成為生物製藥製造中心。因此，許多 CDMO 正在這些地區建立設施，以滿足對廉價生物製劑日益成長的需求。

重組蛋白治療 CDMO 市場 - 關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年），全球市場預計年複合成長率約為 13.98%

根據類型細分，由於傳染病患者病率高，干擾素部分預計將在 2024 年佔據最大市場佔有率。

根據適應症細分，其他細分市場將成為 2024 年領先的適應症細分市場，這是因為高盛行率疾病導致對蛋白質療法的需求很高。

根據來源細分，哺乳動物系統部分是 2024 年領先的來源部分，因為它們在人類糖蛋白中有廣泛的應用。

按地區分類，得益於政府的支持政策和運輸業的發展，北美將成為 2024 年的主要收入來源。

重組蛋白治療 CDMO 市場-細分分析：

全球重組蛋白治療 CDMO 市場根據類型、適應症、來源和地區進行細分。

市場依類型分為五大類：生長激素、干擾素、疫苗、免疫促效劑和其他。干擾素領域佔據市場主導地位。傳染病發病率的不斷上升是刺激該領域成長的主要原因。

根據適應症，市場分為六類：腫瘤學、傳染病、免疫系統疾病、代謝疾病、血液疾病和其他。預計其他部分將佔據最大佔有率。預計預測期內代謝紊亂部分將以最快的速度成長。

根據來源，市場分為三類：哺乳動物系統、微生物系統和其他。哺乳動物系統部分佔據來源部分的最大佔有率。生物藥物、基因工程等應用的不斷增加預計將促進市場成長。

重組蛋白治療 CDMO 市場 - 地理洞察

在全球範圍內，重組蛋白治療CDMO市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區以及中東和非洲地區。北美在重組蛋白治療 CDMO 市場中佔有突出地位。美國已成為重組蛋白藥物生產領域的全球領導者。該國強大的研發基礎設施和發達的生物製藥製造能力促進了市場成長。亞太地區的重組蛋白治療 CDMO 市場可望大幅成長。造成這種情況的因素包括慢性病發病率上升、醫療保健支出增加以及生物技術投資增加，這些都提供了成長機會。中東和非洲的重組蛋白治療 CDMO 市場正在經歷中等成長。

重組蛋白治療 CDMO 市場-競爭格局：

重組蛋白治療 CDMO 市場競爭激烈，幾家主要參與者都在努力增強其服務產品並擴大其市場佔有率。市場參與者為生物製藥（包括重組蛋白）的開發和製造提供全面的服務。一些公司專門從事治療性蛋白質的開發和製造，提供從細胞株開發到商業生產的服務。

介紹
- 按地區分類的細分市場佔有率分析
北美洲
- 概述
- 北美重組蛋白治療 CDMO 主要製造商
- 北美市場規模及預測（按國家/地區）
- 北美市場規模和預測（按類型）
- 北美市場規模及預測（依適應症分類）
- 北美市場規模與預測，依來源分類
- 美國
- 加拿大
歐洲
- 概述
- 歐洲重組蛋白治療 CDMO 主要製造商
- 歐洲市場規模及預測（按國家）
- 歐洲市場規模與預測（按類型）
- 歐洲市場規模及預測（按適應症）
- 歐洲市場規模與預測，按來源
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 瑞典
- 俄羅斯
- 波蘭
- 歐洲其他地區
亞太地區 (APAC)
- 概述
- 亞太地區重組蛋白治療 CDMO 主要製造商
- 亞太地區市場規模及預測（依國家/地區分類）
- 亞太地區市場規模及預測（按類型）
- 亞太地區市場規模及預測（依適應症分類）
- 亞太地區市場規模及預測（依來源分類）
- 中國
- 印度
- 日本
- 韓國
- 澳洲
- 印尼
- 泰國
- 菲律賓
- 亞太地區其他地區
拉丁美洲 (LATAM)
- 概述
- 拉丁美洲重組蛋白治療 CDMO 主要製造商
- 拉丁美洲市場規模及預測（按國家/地區）
- 拉丁美洲市場規模及預測（按類型）
- 拉丁美洲市場規模及預測（依適應症分類）
- 拉丁美洲市場規模及預測（按來源）
- 巴西
- 墨西哥
- 阿根廷
- 哥倫比亞
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 概述
- 中東和非洲重組蛋白治療 CDMO 主要製造商
- MEA 市場規模及預測（依國家/地區分類）
- MEA 市場規模和預測（按類型）
- MEA 市場規模及預測（依適應症分類）
- MEA 市場規模和預測，按來源
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 土耳其
- 阿爾及利亞
- 埃及
- MEA 其他地區

第 11 章：主要供應商分析-重組蛋白治療 CDMO 產業

競爭儀錶板
- Competitive Benchmarking
- Competitive Positioning
公司簡介
- Richter-Helm BioLogics
- Lonza
- Catalent, Inc
- FUJIFILM Diosynth Biotechnologies
- WuXi Biologics
- Curia Global, Inc.
- Batavia Biosciences BV
- AGC Biologics
- Boehringer Ingelheim BioXcellence
- Repligen Corporation
- Therapure BioPharma Inc.
- Cytovance Biologics
- KBI Biopharma
- Abzena
- Patheon
- Others

第 12 章：360 度分析師視角

第 13 章：附錄

研究方法
參考
縮寫
免責聲明
聯絡我們

簡介目錄

Product Code: ANV4798

REPORT HIGHLIGHT

Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.

Recombinant protein therapeutics CDMO is specialized in recombinant protein therapeutics that provides services to biotech and pharmaceutical companies for the development, production, and scaling of protein-based drugs. These companies help in the end-to-end process, including cell line development, upstream and downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.

Recombinant protein therapeutics CDMO Market- Market Dynamics

Increasing demand for biologics and development in bioprocessing technologies are expected to propel market demand

The recombinant protein therapeutics CDMO market growth is driven by increasing demand for biologics, combined with the complexity of their production, has driven pharmaceutical and biotech companies to rely on specialized CDMOs. Biosimilars, which are cost-effective versions of original biologics, are gaining market acceptance, further driving the demand for CDMO services in recombinant protein production, boosting market growth. Single-use bioreactors, continuous manufacturing, and high-yield expression systems (such as CHO and HEK293 cells) have enhanced the efficiency of protein production. Innovations in upstream and downstream processing have improved protein yields, reducing overall production costs and timelines.

The rise of personalized medicine and precision therapeutics has increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in advanced biologics. Further, emerging applications in oncology, rare diseases, and regenerative medicine are fueling market growth. Asia-Pacific, particularly China, India, and South Korea, is becoming a hub for biopharmaceutical manufacturing due to lower costs and supportive government policies. Thus, many CDMOs are setting up facilities in these regions to cater to the growing demand for affordable biologics.

Recombinant protein therapeutics CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.98% over the forecast period (2025-2032)

Based on Type segmentation, the interferons segment was predicted to show maximum market share in the year 2024, due to high prevalence of infectious diseases.

Based on Indication segmentation, the others segment was the leading Indication segment in 2024, due to the high demand for protein therapeutics due to high prevalence disorders.

Based on Source segmentation, the mammalian systems segment was the leading Source segment in 2024, due to their high applications in human glycoproteins.

On the basis of region, Norh America was the leading revenue generator in 2024, owing to supportive government policies & development in transportation sector.

Recombinant protein therapeutics CDMO Market- Segmentation Analysis:

The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.

The market is divided into five categories based on Type: growth hormones, interferons, vaccines, immunostimulant agents, and others. The interferons segment dominates the market. The increasing prevalence of infectious disorders is mainly spurring segment growth.

The market is divided into six categories based on Indication: oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The others segment is expected to hold the largest share. The metabolic disorders segment is expected to grow at the fastest rate over the forecast period.

The market is divided into three categories based on Source: mammalian system, microbial systems, and others. The mammalian systems segment holds the largest share of the source segment. The increasing applications biological drugs, genetical engineering are anticipated to bolster market growth.

Recombinant protein therapeutics CDMO Market- Geographical Insights

Across the world, the Recombinant protein therapeutics CDMO market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a prominent position in the recombinant protein therapeutics CDMO market. The United States has established itself as a global leader in the production of recombinant protein drugs. The country's strong research and development infrastructure and well-developed biopharmaceutical manufacturing capabilities contribute to market growth. The Asia-Pacific region is poised for significant growth in the recombinant protein therapeutics CDMO market. Factors contributing to this include a rising prevalence of chronic diseases, increased healthcare expenditures, and growing investments in biotechnology are offering growth opportunities. The Middle East and Africa are experiencing moderate growth in the recombinant protein therapeutics CDMO market.

Recombinant protein therapeutics CDMO Market- Competitive Landscape:

The recombinant protein therapeutics CDMO market is characterized by intense competition, with several key players striving to enhance their service offerings and expand their market presence. market participants offer a comprehensive range of services for the development and manufacture of biopharmaceuticals, including recombinant proteins. Some of the companies specialize in the development and manufacturing of therapeutic proteins, providing services from cell line development to commercial production.

Recent Developments:

In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, planning to expand production capabilities for its successful weight-loss drugs.

In June 2023, Richter-Helm BioLogics announced the plan for the development of a production site in Bovenau, Europe.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS

Richter-Helm BioLogics
Lonza
Catalent, Inc
FUJIFILM Diosynth Biotechnologies
WuXi Biologics
Curia Global, Inc.
Batavia Biosciences B.V.
AGC Biologics
Boehringer Ingelheim BioXcellence
Repligen Corporation
Therapure BioPharma Inc.
Cytovance Biologics
KBI Biopharma
Abzena
Patheon
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

Growth hormones
Interferons
Vaccines
Immunostimulant agents
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

Oncology
Infectious Diseases
Immunological disorders
Metabolic disorders
Hematological disorders
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032

Mammalian system
Microbial systems
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Recombinant Protein Therapeutics CDMO Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Recombinant Protein Therapeutics CDMO Market Snippet by Type
- 2.1.2. Recombinant Protein Therapeutics CDMO Market Snippet by Indication
- 2.1.3. Recombinant Protein Therapeutics CDMO Market Snippet by Source
- 2.1.4. Recombinant Protein Therapeutics CDMO Market Snippet by Country
- 2.1.5. Recombinant Protein Therapeutics CDMO Market Snippet by Region
2.2. Competitive Insights

3. Recombinant Protein Therapeutics CDMO Key Market Trends

3.1. Recombinant Protein Therapeutics CDMO Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Recombinant Protein Therapeutics CDMO Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Recombinant Protein Therapeutics CDMO Market Opportunities
3.4. Recombinant Protein Therapeutics CDMO Market Future Trends

4. Recombinant Protein Therapeutics CDMO Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Recombinant Protein Therapeutics CDMO Market Landscape

6.1. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Recombinant Protein Therapeutics CDMO Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 7.1.2. Growth hormones
- 7.1.3. Interferons
- 7.1.4. Vaccines
- 7.1.5. Immunostimulant agents
- 7.1.6. Others

8. Recombinant Protein Therapeutics CDMO Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Infectious Diseases
- 8.1.4. Immunological disorders
- 8.1.5. Metabolic disorders
- 8.1.6. Hematological disorders
- 8.1.7. Others

9. Recombinant Protein Therapeutics CDMO Market - By Source

9.1. Overview
- 9.1.1. Segment Share Analysis, By Source, 2024 & 2032 (%)
- 9.1.2. Mammalian system
- 9.1.3. Microbial systems
- 9.1.4. Others

10. Recombinant Protein Therapeutics CDMO Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Richter-Helm BioLogics
- 11.2.2. Lonza
- 11.2.3. Catalent, Inc
- 11.2.4. FUJIFILM Diosynth Biotechnologies
- 11.2.5. WuXi Biologics
- 11.2.6. Curia Global, Inc.
- 11.2.7. Batavia Biosciences B.V.
- 11.2.8. AGC Biologics
- 11.2.9. Boehringer Ingelheim BioXcellence
- 11.2.10. Repligen Corporation
- 11.2.11. Therapure BioPharma Inc.
- 11.2.12. Cytovance Biologics
- 11.2.13. KBI Biopharma
- 11.2.14. Abzena
- 11.2.15. Patheon
- 11.2.16. Others